# [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis

> **NCT02700763** · NA · TERMINATED · sponsor: **University Medical Center Groningen** · enrollment: 1 (actual)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** [18F]dabrafenib molecular imaging

## Key facts

- **NCT ID:** NCT02700763
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-06
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to the very low inlcusion rate and the current COVID-19 pandemic.
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700763, "[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02700763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*